Yousif Capital Management LLC Has $2.09 Million Position in Halozyme Therapeutics, Inc. $HALO

Key Points

• Yousif Capital Management LLC reduced its stake in Halozyme Therapeutics by 11.3%, now holding about $2.09 million worth of shares after selling 5,104 shares in the second quarter.
• Equities research analysts are optimistic about Halozyme Therapeutics; Weiss Ratings upgraded the stock to "buy" and several firms raised their price targets significantly.
• Insider selling was noted as the CFO and CEO both sold shares recently; in total, insiders sold 108,227 shares worth nearly $7.8 million in the last quarter.

Yousif Capital Management LLC lowered its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 11.3% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 40,076 shares of the biopharmaceutical company's stock after selling 5,104 shares during the period. Yousif Capital Management LLC's holdings in Halozyme Therapeutics were worth $2,085,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of HALO. Wealth Preservation Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the 1st quarter valued at $32,000. SVB Wealth LLC acquired a new stake in shares of Halozyme Therapeutics during the 1st quarter valued at $33,000. Bessemer Group Inc. boosted its stake in shares of Halozyme Therapeutics by 62.9% during the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 207 shares during the period. Brooklyn Investment Group boosted its stake in shares of Halozyme Therapeutics by 1,558.1% during the 1st quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 670 shares during the period. Finally, Park Place Capital Corp boosted its stake in shares of Halozyme Therapeutics by 20.1% during the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock valued at $69,000 after buying an additional 182 shares during the period. Institutional investors and hedge funds own 97.79% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on HALO shares. Weiss Ratings raised shares of Halozyme Therapeutics from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, October 8th. Benchmark lifted their price objective on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a "buy" rating in a research note on Wednesday, September 24th. Morgan Stanley lifted their price objective on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the company an "overweight" rating in a research note on Monday, August 18th. Leerink Partnrs raised shares of Halozyme Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Tuesday, October 14th. Finally, Leerink Partners raised shares of Halozyme Therapeutics from an "underperform" rating to a "market perform" rating and set a $70.00 price objective for the company in a research note on Tuesday, October 14th. Five equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of "Hold" and a consensus target price of $73.00.

Halozyme Therapeutics Stock Up 0.2%

HALO stock opened at $67.03 on Friday. The firm has a market cap of $7.84 billion, a PE ratio of 15.34, a PEG ratio of 0.36 and a beta of 1.16. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. Halozyme Therapeutics, Inc. has a 1 year low of $42.01 and a 1 year high of $79.50. The company has a fifty day simple moving average of $71.56 and a 200 day simple moving average of $62.09.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, topping analysts' consensus estimates of $1.23 by $0.31. The firm had revenue of $325.72 million during the quarter, compared to analyst estimates of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The business's revenue was up 40.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.91 EPS. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 20,000 shares of the business's stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total transaction of $1,514,200.00. Following the completion of the transaction, the chief financial officer owned 24,306 shares of the company's stock, valued at $1,840,207.26. The trade was a 45.14% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $75.35, for a total transaction of $1,507,000.00. Following the transaction, the chief executive officer directly owned 733,719 shares of the company's stock, valued at approximately $55,285,726.65. This represents a 2.65% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 108,227 shares of company stock valued at $7,779,595 in the last quarter. Insiders own 2.40% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.